Immunization with the 7-valent conjugate pneumococcal vaccine: Impact evaluation, continuing surveillance and future perspectives

Vaccine

Volumn 27, Issue 25-26, 2009, Pages 3285-3290

  Bechini, Angela ^a   Boccalini, Sara ^a   Bonanni, Paolo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Correlates of protection; Direct and indirect protection; Pneumococcal conjugate vaccine; Surveillance

Indexed keywords

ANTIBIOTIC AGENT; PLACEBO; PNEUMOCOCCUS VACCINE;

ACUTE OTITIS MEDIA; ARTICLE; BACTEREMIA; CANADA; CLINICAL EVALUATION; CLINICAL TRIAL; CONJUGATE; DEVELOPMENTAL STAGE; DISEASE SURVEILLANCE; DRUG EFFICACY; DRUG SURVEILLANCE PROGRAM; GROUPS BY AGE; HEALTH CARE DELIVERY; HUMAN; IMMUNIZATION; MORTALITY; OTITIS MEDIA; PNEUMOCOCCAL MENINGITIS; PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEROTYPE; THORAX RADIOGRAPHY; WORLD HEALTH ORGANIZATION;

HUMANS; IMMUNIZATION; OTITIS MEDIA; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; PRODUCT SURVEILLANCE, POSTMARKETING; VACCINES, CONJUGATE; WORLD HEALTH ORGANIZATION;

EID: 67349181317     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.01.058     Document Type: Article

References (35)

1. Bogaert D., de Groot R., and Hermans P.W.M. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis 4 (2004) 144-154
2. Yeh S.H., Zangwill K.M., Lee H., Chang S.J., Wong V.I., Greenberg D.P., et al. Heptavalent pneumococcal vaccine conjugated to outer membrane protein of Neisseria meningitidis serogroup b and nasopharyngeal carriage of Streptococcus pneumoniae in infants. Vaccine 21 19-20 (2003) 2627-2631
3. Klugman K.P., and Koornhof H.J. Drug resistance patterns and serogroups or serotypes of pneumococcal isolates from cerebrospinal fluid or blood, 1979-1986. J Infect Dis 158 5 (1988) 956-964
4. Dagan R., Yagupsky P., Goldbart A., Wasas A., and Klugman K. Increasing prevalence of penicillin-resistant pneumococcal infections in children in southern Israel: implications for future immunization policies. Pediatr Infect Dis J 13 9 (1994) 782-786
5. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Lexau C., Reingold A., et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 343 26 (2000) 1917-1924
6. Shinefield H.R., Black S., Ray P., Chang I., Lewis N., Fireman B., et al. Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. Pediatr Infect Dis J 18 9 (1999) 757-763
7. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., Lynfield R., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 348 18 (2003) 1737-1746
8. Grijalva C.G., Nuorti J.P., Arbogast P.G., Martin S.W., Edwards K.M., and Griffin M.R. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 369 (2007) 1179-1186
9. C.D.C. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction-eight states, 1998-2005. MMWR 57 (2008) 144-148
10. Klugman K.P. Efficacy of pneumococcal conjugate vaccines and their effect on carriage and antimicrobial resistance. Lancet Infect Dis 1 (2001) 85-91
11. Gaudelus J., Cohen R., and Hovart J. Couverture vaccinale du vaccin pneumococcique heptavalent conjugué en 2007, comparaison avec les années précédentes et les autres vaccins pédiatriques: analyse des carnets de santé. Médecine et Enfance 27 5 (2007) 1-4. http://www.medecine-et-enfance.net/ [Available from: http://www.medecine-et-enfance.net/]
12. Lepoutre A., Varon E., Georges S., Gutmann L., and Lévy-Bruhl D. Impact of infant pneumococcal vaccination on invasive pneumococcal diseases in France, 2001-2006. Euro Surveill 13 35 (2008). http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId%20=%2018962 [pii = 189962. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId = 18962]
13. Kyaw M.H., Lynfield R., Schaffner W., Craig A.S., Hadler J., Reingold A., et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 354 14 (2006) 1455-1463
14. Lexau C.A., Lynfield R., Danila R., Pilishvili T., Facklam R., Farley M.M., et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 294 16 (2005) 2043-2051
15. CDC. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease - United States, 1998-2003. MMWR 54 36 (2005) 893-897
16. Ray G.T., Whitney C.G., Fireman B.H., Ciuryla V., and Black S.B. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects. Pediatr Infect Dis J 25 6 (2006) 494-501
17. Wardlaw T., Salama P., Johansson E.W., and Mason E. Pneumonia: the leading killer of children. Lancet 368 9541 (2006) 1048-1050
18. Black S.B., Shinefield H.R., Ling S., Hansen J., Fireman B., Spring D., et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 21 9 (2002) 810-815
19. Hansen J., Black S., Shinefield H., Cherian T., Benson J., Fireman B., et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using world health organization standardized interpretation of chest radiographs. Pediatr Infect Dis J 25 9 (2006) 779-781
20. Lucero M.G., Dulalia V.E., Parreno R.N., Lim-Quianzon D.M., Nohynek H., Makela H., et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and pneumonia with consolidation on x-ray in children under two years of age. Cochrane Database Syst Rev 4 (2004) CD004977
21. McEllistrem M.C., Adams J., Mason E.O., and Wald E.R. Epidemiology of acute otitis media caused by Streptococcus pneumoniae before and after licensure of the 7-valent pneumococcal protein conjugate vaccine. J Infect Dis 188 11 (2003) 1679-1684
22. Straetemans M., Sanders E.A.M., Veenhoven R.H., Schilder A.G., Damoiseaux R.A., and Zielhuis G.A. Pneumococcal vaccines for preventing otitis media. Cochrane Database Syst Rev 1 (2004) CD001480
23. Poehling K.A., Szilagyi P.G., Grijalva C.G., Martin S.W., LaFleur B., Mitchel E., et al. Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal coniugate vaccine. Pediatrics 119 4 (2007) 707-715
24. Grijalva C.G., Poehling K.A., Nuorti J.P., Zhu Y., Martin S.W., Edwards K.M., et al. National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Pediatrics 118 3 (2006) 865-873
25. European Medicines Agency. Prevenar - European Public Assessment Report. Available from: http://www.emea.europa.eu/humandocs/Humans/EPAR/prevenar/prevenar.htm.
26. World Health Organization. Pneumococcal conjugate vaccine for childhood immunization - WHO position paper. Weekly Epidemiological Record 82 (2007) 93-104
27. Azzari C., Moriondo M., Indolfi G., Massai C., Becciolini L., de Martino M., et al. Molecular detectionmethods and serotyping performed directly on clinical samples improve diagnostic sensitivity and reveal increased incidence of invasive disease by Streptococcus pneumoniae in Italian children. J Med Microbiol 57 (2008) 1205-1212
28. Clarke S.C. Detection of Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae in blood and cerebrospinal fluid using fluorescence-based PCR. Methods Mol Biol 345 (2006) 69-77
29. Corless C.E., Guiver M., Borrow R., Edwards-Jones V., Fox A.J., and Kaczmarski E.B. Simultaneous detection of Neisseria meningitidis, Haemophilus influenzae, and Streptococcus pneumoniae in suspected cases of meningitis and septicemia using real-time PCR. J Clin Microbiol 39 4 (2001) 1553-1558
30. Plotkin S.A. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis 47 3 (2008) 401-409
31. Nahm M.H., Olander J.V., and Magyarlaki M. Identification of cross-reactive antibodies with low opsonophagocytic activity for Streptococcus pneumoniae. J Infect Dis 176 (1997) 698-703
32. Jódar L., Butler J., Carlone G., Dagan R., Goldblatt D., Käyhty H., et al. Serological criteria for evaluation and licensure of newpneumococcal conjugate vaccine formulations for use in infants. Vaccine 21 23 (2003) 3265-3272
33. Siber G.R., Chang I., Baker S., Fernsten P., O'Brien K.L., Santosham M., et al. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine 25 19 (2007) 3816-3826
34. World Health Organization. Recommendations for the production and control of pneumococcal conjugate vaccines. WHO Technical Report Series. WHO Technical Report Series, No. 927,2005. Annex 2:64-98. Available from: http://www.who.int/biologicals/publications/trs/areas/vaccines/pneumo/AN NEX%202%20PneumococcalP64-98.pdf.
35. Jokinen J.T., Ahman H., Kilpi T.M., Mäkelä P.H., and Käyhty M.H. Concentration of antipneumococcal antibodies as a serological correlate of protection: an application to acute otitis media. J Infect Dis 190 3 (2004) 545-550